Sarepta Therapeutics released updated safety data for Elevidys, its gene therapy for Duchenne muscular dystrophy, reporting zero ambulatory deaths related to acute liver failure among over 1,000 treated patients. However, acute liver injury was observed in a notable proportion, with a small fraction requiring hospitalization. Non-ambulatory patient treatments remain paused following fatalities and ongoing FDA investigations.